Web notes  
January 2013

[Oncology archives]

1. Bechan GI, Lee DW, Zajonc DM, Heckel D, Xian R, Throsby M, van Meijer M, Germeraad WT, Kruisbeek AM, Egeler RM, Arceci RJ. Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity. Br J Haematol. 2012 Nov;159(3):299-310.
Key words: phage, monoclonal, cytolytic

2. Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22;120(22):4285-91.
Key words: sickle cell, cyclophosphamide, donor

3. Isaacs JT, Antony L, Dalrymple S, Brennen WN, Gerber S, Hammers H, Wissing MD, Kachhap SK, Luo J, Xing L, Bjork P, Olsson A, Björk A, Leanderson T. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2012 Nov 13. [Epub ahead of print]
Key words: HDAC4, allosteric, signaling

4. Jackson CM, Flies DB, Mosse CA, Parwani A, Hipkiss EL, Drake CG. Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. Prostate. 2012 Nov 5. doi: 10.1002/pros.22606. [Epub ahead of print]
Key words: prostatisis, aotoimmune

5. Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012 Nov;97(11):1736-42.
Key words: leukemia, mitoxantrone, flavopiridol

6. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Nov 19. [Epub ahead of print]
Key words: arabinoside, leukemia, selective checkpoint

7. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012 Nov 28;4(162):162ra154.
Key words: circulation, chromosomal, sequencing

8. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable Cancer Regression Off-treatment and Effective Re-induction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res. 2012 Nov 20. [Epub ahead of print]
Key words: cancer regression, anti-PD, Re-induction

9. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):E3367-76.
Key words: breast cancer, hypoxia, coactivator

10. Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012 Dec;17(4):469-92.
Key words: papillomavirus, vaccine

11. Rais R, Zhao M, He P, Xu L, Deeken JF, Rudek MA. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomed Chromatogr. 2012 Nov;26(11):1315-24.
Key words: sunitinib, human plasma, pharmacokinetic

12. Ren YR, Chaerkady R, Hu S, Wan J, Qian J, Zhu H, Pandey A, Kern SE. Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin. J Proteome Res. 2012 Nov 2;11(11):5301-10.
Key words: mesothelin, therapeutic, control locus

13. Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012 Nov 15;120(20):4205-14.
Key words: Myeloid, terminal, FLT3

14. Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J. 2012 Nov;18(6):642-52.
Key words: vaccines, pancreatic cancer


Return to top of Publications - Oncology

Search Publications
January 2013 articles:
Visit Animal Care and Use Committee Website
Current Classes
Funding from Foundations/Private Sources
Maryland Innovation Initiative
Funding For Prostate Cancer Research
Damon Runyon Clinical Investigator Award for 2013
Dana Foundation's David Mahoney Neuroimaging Program (Program in Brain and Immuno-Imaging)
National Marfan Foundation Victor A. McKusick Fellowship Program
Request for Proposals from the Center for Musculoskeletal Research - Pilot and Feasibility Studies
American Asthma Foundation Scholar Program
2013 Young Investigator Grant for Probiotics Research

This Month's Departmental Listings

Upcoming Deadlines for January, February and March

Genetic Resources Core Facility (GRCF)


JHM AppointmentsEmployment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM 


                                                                                                                                                           The Web Center